SERUM LEVEL OF ISCHEMIA MODIFIED ALBUMIN AND TOTAL OXIDATIVE STRESS AS A BIOMARKER FOR DIAGNOSIS OF ISCHEMIC HEART DISEASE PRONE TO MYOCARDIAL INFARCTION
Main Article Content
Keywords
Serum, Ischemia Modified Albumin, Total oxidative stress, Myocardial infarction
Abstract
Background: Albumin is the most abundant protein in human blood plasma and its level may vary according to age. In neonates, its level is approximately 3.9 g/dl. It decreases to 2.8 g/dl at 9 months of age and increases slowly (3.5 g/dl to 5.5 g/dl) until the adult age. For albumin perform its main functions - to maintain the colloid osmotic pressure of intravascular fluid and to bind several substances in blood plasma such as bilirubin, fatty acid, calcium ion, magnesium ion and various drugs.
Objective: To determine the Serum level of Ischemia Modified Albumin and total oxidative stress as a biomarker for diagnosis of ischemic heart disease prone to myocardial infarction.
Methodology: This retrospective study was done at the Department of Biochemistry Mohtarma Benazir Bhutto Shaheed medical college Mirpur. The study duration was one year from March 2023 to March 2024. A total of 120 patients were enrolled in our study. Patients were divided into case group and control group. Case group was further categorized as group A, group B and group C. In group A, subjects with diagnosed Ischemic Heart Disease (IHD), in group B, subjects performed PCI and in group C, subjects with diagnosed MI were included. In control group, normal, healthy subjects with same age as matched to case groups were selected for comparison. IMA assayed by using colorimetric method using dithiothreitol (DTT). Troponin-I was determined by using ELISA kit method. Superoxide Dismutase (SOD) and total antioxidant capacity (TAC) were determined by spectrophotometer. To determine triglycerides (TAG), GOD- PAP method on selectra Pro Sa fully automated analyzer was used. Serum total cholesterol was analyzed by Chod-Pap method on selectra Pro Sa fully automated analyzer. Homogeneous enzymatic colorimetric method was used for estimation of high-density lipoprotein (HDL)– cholesterol and direct method was used for low density lipoprotein (LDL)-cholesterol measurement. All the controls were also subjected to measurement of above biochemical parameters along with estimation of serum IMA. Data was analyzed using Statistical Package for Social Sciences (SPSS), version 24.0.
Results: A total of 120 patients were enrolled in our study with 60 in control group and 60 in case group. Statistically significant results were observed for total cholesterol, HDL and LDL (p=˂.05), while results for TAG were insignificant (p=˃0.05). High mean (± SD) values of IMA (u/ml) were observed for group C (96.11 ± 11.09) followed by group B (88 ± 4.99) and group A (83.11 ± 9.66) as compare to control group (23.99 ± 8.84). Statistically significant results were observed for IMA, troponin-I, SOD and TAC between group A, B, C and control group.
References
2. Gottlieb MG. Associação entre síndrome metabólica, albumina modificada pela isquemia (IMA) e biomarcadores aterotrombóticos. Porto Alegre: Pontifícia Universidade Católica do Rio Grande do Sul, Programa de Pós-Graduação em Medicina e Ciências da Saúde; 2009.
3. Cichota LC. Avaliação da albumina modificada pela isquemia na anemia associada à doença renal crônica [dissertation]. Santa Maria: Universidade Federal de Santa Maria, Programa de Pós-Graduação em Ciências da Saúde; 2007.
4. Can M, Demirtas S, Polat O, Yildiz A. Evaluation of effects of ischemia on the albumin cobalt binding (ACB) assay in patients exposed to trauma. Emerg Med J. 2006;23:537-9.
5. Christenson RH, Duh SH, Sanhai WR, et al. Characteristics of an albumin cobalt binding test for assesment of acute coronary syndrome patients: a multicenter study. Clin Chem. 2001;47(3):464-70.
6. Hjortshøj S, Kristensen SR, Ravkilde J. Diagnostic value of ischemiamodified albumin in patients with suspected acute coronary syndrome. Am J Emerg Med. 2010;28(2):170-6.
7. Andrade RB, Gemelli T, Rojas DB, Funchal C, Dutra-Filho CS, Wannmacher CM. Tyrosine inhibits creatine kinase activity in cerebral cortex of young rats. Metab Brain Dis. 2011;26(3):221-7.
8. Maynard SJ, Menown IB, Adgey AA. Troponin T or troponin I as cardiac markers in ischaemic heart disease. Heart. 2000;83(4):371-3.
9. Hamm CW, Giannitsis E, Katus HA. Cardiac troponin elevations in patients without acute coronary syndrome. Circulation. 2002;106(23):2871-2.
10. Kaiser RM, Azambuja AA, Lunardelli A, Oliveira JR. Troponina Ic como marcador na insuficiência cardíaca. Rev Bras Análises Clínicas. 2004;36(1):39-41.
11. Selker HP, Zalenski RJ, Antman EM, et al. An evaluation of technologies for identifying acute cardiac ischemia in the emergency department: a report from a National Heart Attack Alert Program Working Group. Ann Emerg Med. 1997;29(1):13-87.
12. Ellidag HY, Eren E, Yilmaz N, Cekin Y. Oxidative stress and ischemiamodified albumin in chronic ischemic heart failure. Redox Report. 2014;19(3):118-23.
13. Gemelli T, Andrade RB, Rojas DB, et al. Effects of ß-alanine administrations on selected parameters of oxidative stress and phosphoryltransfer network in cerebral cortex and cerebellum of rats. Mol Cell Biochem. 2013;380(1-2):161-70.
14. Abadie JM, Blassingame CL, Bankson DD. Albumin cobalt binding assay to rule out acute coronary syndrome. Ann Clin Lab Sci. 2005;35(1):66-72.
15. Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co2+ and Ni2+ binding amino-acid residues of the N-terminus of human albumin: an insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem. 2001;268(1):42-7.
16. Bhagavan NV, Lai EM, Rios PA, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem. 2003;49(4):581-5.
17. Sahin, A., S. Turkoglu, N. Tunc, D. Duzenci, O.A. Solmaz, I.H. Bahcecioglu and M. Yalniz Is ischemia- modified albumin a reliable tool for the assessment of acute pancreatitis? Therapeutics and clinical risk management, (2018). 14: 627-635.
18. Güldoğan, C.E., M.O. Kılıç, I. Balamir, M. Tez and T. Turhan Correlation between ischemia-modified albumin and Ranson score in acute pancreatitis. Turkish Journal of Trauma and Emergency Surgery, (2017). 23(6): 472-476.
19. Chacko, S., S. Haseeb, B.M. Glover, D. Wallbridge and A. Harper The role of biomarkers in the diagnosis and risk stratification of acute coronary syndrome. Future science OA, (2017).4(1), FSO251.doi:10.4155/fsoa-2017- 0036.
20. Bonorino, N.F., A. Lunardelli and J.R. Oliveira Use of ischemia modified albumin for the diagnosis of myocardial infarction. Journal Brasileiro de Patologia e Medicina Laboratorial, (2015). 51(6): 383-388. [Last assessed on 13-12-18].
21. Nepal, M., S. Jaisawal, M. Guragain, P. Kafle, S. Mukkera, R.K. Ghimire, B. Simmonds, U.M. Harris and S. Berger Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative-Ischemic Conditions. Journal of Cardiovascular Disease Research, (2017). 8(4): 112- 116
22. Guntas, G., A. Sahin, S. Duran, R. Kahraman, I. Duran, C. Sonmez, T. Calhan and H.M. Sokmen Evaluation of Ischemia-Modified Albumin in Patients with Inflammatory Bowel Disease. Clinical laboratory, (2017). 63(2): 341- 347.
23. Topaloglu, N., A. Kucuk, M. Tekin, S. Yildirim, M. Erabas, H.A. Kiraz, D.U. Cakir and H. Erdem Serum ischemia-modified albumin levels in experimental model of acute pancreatitis. J Coll Physicians Surg Pak, (2015). 25(6): 395–398.
24. Pan, D. and D. Li. Role of ischemia-modified albumin in patients with acute decompensated heart failure. Anatolian Journal of Cardiology, (2016).15(8): 618-619.